1. Home
  2. STTK vs GBIO Comparison

STTK vs GBIO Comparison

Compare STTK & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • GBIO
  • Stock Information
  • Founded
  • STTK 2016
  • GBIO 2016
  • Country
  • STTK United States
  • GBIO United States
  • Employees
  • STTK N/A
  • GBIO N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • GBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • STTK Health Care
  • GBIO Health Care
  • Exchange
  • STTK Nasdaq
  • GBIO Nasdaq
  • Market Cap
  • STTK 56.8M
  • GBIO 64.8M
  • IPO Year
  • STTK 2020
  • GBIO 2020
  • Fundamental
  • Price
  • STTK $1.12
  • GBIO $0.88
  • Analyst Decision
  • STTK Hold
  • GBIO Strong Buy
  • Analyst Count
  • STTK 3
  • GBIO 2
  • Target Price
  • STTK $2.00
  • GBIO $6.50
  • AVG Volume (30 Days)
  • STTK 182.2K
  • GBIO 581.0K
  • Earning Date
  • STTK 02-27-2025
  • GBIO 03-05-2025
  • Dividend Yield
  • STTK N/A
  • GBIO N/A
  • EPS Growth
  • STTK N/A
  • GBIO N/A
  • EPS
  • STTK N/A
  • GBIO N/A
  • Revenue
  • STTK $6,435,000.00
  • GBIO $18,582,000.00
  • Revenue This Year
  • STTK $313.04
  • GBIO $212.74
  • Revenue Next Year
  • STTK N/A
  • GBIO N/A
  • P/E Ratio
  • STTK N/A
  • GBIO N/A
  • Revenue Growth
  • STTK 382.75
  • GBIO 514.08
  • 52 Week Low
  • STTK $0.94
  • GBIO $0.75
  • 52 Week High
  • STTK $11.76
  • GBIO $4.65
  • Technical
  • Relative Strength Index (RSI)
  • STTK 43.75
  • GBIO 28.66
  • Support Level
  • STTK $1.13
  • GBIO $0.85
  • Resistance Level
  • STTK $1.39
  • GBIO $1.01
  • Average True Range (ATR)
  • STTK 0.11
  • GBIO 0.12
  • MACD
  • STTK 0.00
  • GBIO 0.00
  • Stochastic Oscillator
  • STTK 18.18
  • GBIO 7.50

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: